<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00682513</url>
  </required_header>
  <id_info>
    <org_study_id>1688159</org_study_id>
    <secondary_id>BG05-556</secondary_id>
    <secondary_id>1R01NS058949-01A1</secondary_id>
    <secondary_id>IRB00007686</secondary_id>
    <secondary_id>1704511</secondary_id>
    <nct_id>NCT00682513</nct_id>
  </id_info>
  <brief_title>Studies of the Variable Phenotypic Presentations of Rapid-Onset Dystonia Parkinsonism and Other Movement Disorders</brief_title>
  <official_title>Clinical, Genetic, and Cellular Consequences of Mutations in the NA,K-ATPase ATP1A3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to identify persons with rapid-onset dystonia-parkinsonism&#xD;
      (RDP) or mutations of the RDP gene, document prevalence of the disease, and map its natural&#xD;
      history.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rapid-onset dystonia-parkinsonism (RDP) is a rare, movement disorder with variable&#xD;
      characteristics ranging from sudden onset (hours to days) of severe dystonic spasms to&#xD;
      gradual onset of writer's cramp. RDP has elements of both dystonia and Parkinson's&#xD;
      disease-two neurological diseases with motor and neuropsychological symptoms that hinder the&#xD;
      quality of life. An internal trigger associated with extreme physiological stress has been&#xD;
      reported prior to abrupt symptom onset of RDP.&#xD;
&#xD;
      This study, which is a continuation of an earlier study begun by Dr. Allison Brashear, aims&#xD;
      to more clearly identify the characteristics associated with RDP and to explore whether&#xD;
      mutations in the RDP gene are associated with atypical dystonias, Parkinson's disease, and&#xD;
      other movement disorders.&#xD;
&#xD;
      The study involves in-person or remote (telemedicine) neurological assessments and blood&#xD;
      samples for genetic analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">July 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>RDP Severity</measure>
    <time_frame>Visit 1 (baseline)</time_frame>
    <description>History of symptom onset and duration will be obtained and current degree of severity assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of neuropsychiatric disease</measure>
    <time_frame>Will be assessed at Visits 1 (baseline) and 2 (24 months), approximately 2 years apart</time_frame>
    <description>Psychiatric interview and cognitive assessment will be performed to examine presence or absence of symptoms.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Dystonia</condition>
  <condition>Parkinsonism</condition>
  <arm_group>
    <arm_group_label>ATP1A3 Mutation</arm_group_label>
    <description>Those with RDP, AHC, unaffected carriers of ATP1A3 mutations, and non-carrying family members</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, tissue (saliva samples)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Selection will take place predominantly via primary care clinics, i.e., physician referrals&#xD;
        when patients present with a movement disorder suspicious for RDP.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinical presentation consistent with ATP1A3 disease (RDP, AHC) or confirmed diagnosis&#xD;
             of RDP or AHC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allison Brashear, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dean, University of California, Davis School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Californioa, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.atp1a3diseases.org/</url>
    <description>ATP1A3 diseases study website</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 20, 2008</study_first_submitted>
  <study_first_submitted_qc>May 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2008</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dystonia</keyword>
  <keyword>parkinsonism</keyword>
  <keyword>rapid-onset dystonia-parkinsonism</keyword>
  <keyword>RDP</keyword>
  <keyword>Alternating Hemiplegia of Childhood</keyword>
  <keyword>AHC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

